AGF Management Ltd. Sells 540,325 Shares of IQVIA Holdings Inc. (NYSE:IQV)

AGF Management Ltd. reduced its stake in IQVIA Holdings Inc. (NYSE:IQV) by 93.9% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 35,260 shares of the medical research company’s stock after selling 540,325 shares during the period. AGF Management Ltd.’s holdings in IQVIA were worth $6,929,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Inspire Advisors LLC boosted its position in shares of IQVIA by 10.1% in the 4th quarter. Inspire Advisors LLC now owns 2,584 shares of the medical research company’s stock worth $508,000 after purchasing an additional 236 shares during the last quarter. Citizens Financial Group Inc. RI lifted its holdings in IQVIA by 14.5% during the fourth quarter. Citizens Financial Group Inc. RI now owns 2,820 shares of the medical research company’s stock worth $554,000 after acquiring an additional 357 shares in the last quarter. Independent Advisor Alliance lifted its holdings in IQVIA by 49.7% during the fourth quarter. Independent Advisor Alliance now owns 1,729 shares of the medical research company’s stock worth $340,000 after acquiring an additional 574 shares in the last quarter. Meriwether Wealth & Planning LLC bought a new position in IQVIA during the fourth quarter worth about $505,000. Finally, Daiwa Securities Group Inc. lifted its holdings in IQVIA by 17.7% during the fourth quarter. Daiwa Securities Group Inc. now owns 44,302 shares of the medical research company’s stock worth $8,706,000 after acquiring an additional 6,651 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on IQV shares. StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a report on Wednesday. Stephens started coverage on IQVIA in a report on Friday, December 20th. They set an “overweight” rating and a $250.00 target price on the stock. Robert W. Baird reduced their target price on IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a report on Tuesday, January 21st. Citigroup reduced their target price on IQVIA from $225.00 to $210.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $270.00 price target on shares of IQVIA in a report on Monday, February 10th. Five research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $249.05.

IQVIA Price Performance

NYSE:IQV opened at $185.47 on Thursday. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The stock’s 50-day simple moving average is $197.14 and its 200 day simple moving average is $211.59. The company has a market cap of $32.70 billion, a P/E ratio of 24.73, a P/E/G ratio of 1.99 and a beta of 1.50. IQVIA Holdings Inc. has a 52-week low of $179.28 and a 52-week high of $261.72.

IQVIA (NYSE:IQV) last released its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.